BioPlus Acquisition Corp.
BIOS · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.74 | 0.01 | -14.93 | 0.31 |
| FCF Yield | -0.34% | -0.13% | -0.00% | -0.06% |
| EV / EBITDA | -207.96 | -912.48 | -19,227.34 | -1,032.58 |
| Quality | ||||
| ROIC | -0.94% | -0.11% | -0.13% | -0.12% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.71 | -0.14 | -0.15 | -0.28 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -178.49% | -36.93% | -22.85% | -75.58% |
| Safety | ||||
| Net Debt / EBITDA | -4.10 | -18.05 | -15.28 | -16.87 |
| Interest Coverage | 0.00 | 0.00 | -0.28 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |